Navigation Links
New Review Describes the use of Safinamide in Parkinson's Disease
Date:1/19/2017

LONDON, January 19, 2017 /PRNewswire/ --

New Review of Safinamide - A New Therapeutic Option to Address Motor Symptoms and Motor Complications in Mid- to Late-stage Parkinson's Disease

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO)

C Warren Olanow, Fabrizio Stocchi, European Neurological Review,2016;11(Suppl. 2): 2-15, http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late

Published recently in a supplement to European Neurological Review the peer-reviewed journal from touchNEUROLOGY, C Warren Olanow  et al, discusses a new therapeutic option in Parkinson's disease (PD). Levodopa is the cornerstone of therapy for PD and remains the most effective treatment available. Over time, however, the beneficial motor response to levodopa gradually shortens (this is known as 'wearing off') and motor complications (motor fluctuations and dyskinesias) increasingly affect so-called 'on-time'. The risk of developing motor complications is strongly linked to levodopa dose, independently of other predictive factors including disease severity. This provides a strong rationale for using other drugs, either alone or in combination with low-dose levodopa, to preserve the efficacy of levodopa for as long as possible. Several classes of drugs, including dopamine agonists, catechol-O-methyltransferase inhibitors, and monoamine oxidase B (MAO-B) inhibitors, are used as add-ons to levodopa, but all have significant drawbacks. Recently, safinamide (Xadago®) was approved for the treatment of PD patients as an add-on therapy to levodopa alone or in combination with other PD agents in mid- to late-stage fluctuating patients. Safinamide has a dual mechanism of action that includes modulation of dopaminergic metabolism through selective, reversible inhibition of MAO-B, and blockade of voltage and use-dependent sodium (Na+) channels, leading to inhibition of stimulated glutamate release. This article reviews the pathophysiology of PD and current treatment options, together with a comprehensive discussion of the pharmacokinetic, preclinical and clinical data relating to safinamide, including results from the 016/018 and the Safinamide in Idiopathic Parkinson's Disease With Motor Fluctuations, as add-on to Levodopa (SETTLE) studies and exploratory post hoc analyses. In these pivotal studies, safinamide 50-100 mg/day demonstrated efficacy in the treatment of motor fluctuations and motor symptoms in stabilised levodopa patients (improving the Unified Parkinson's Disease Rating Scale III score, and motor complications, as indicated by a significant reduction versus placebo in the primary endpoint of on-time without troublesome dyskinesias). Safinamide treatment was also effective for improving other motor complications (such as 'off-time', early-morning akinesia), motor symptoms, non-motor symptoms, activities of daily living and quality of life. These effects have been proved in the short term (six months) and maintained in the long term (24 months). Together, the data suggest that safinamide could be an appropriate choice as a first-line add-on therapy to levodopa in PD patients experiencing motor fluctuations.

The full peer-reviewed, open-access article is available here:

http://www.touchneurology.com/articles/safinamide-new-therapeutic-option-address-motor-symptoms-and-motor-complications-mid-late

Disclosure: Fabrizio Stocchi receives consultant fees and honoraria for educational symposia from Zambon and has been a consultant to TEVA, Novartis, GSK, Lundbeck, Merck Serono, MSD, UCB, Chiesi Pharma, IMPAX, Newron, Zambon and Britannia. C. Warren Olanow receives consultant fees from Abbvie, Addex, Lundbeck, Newron, Novartis, Teva, Zambon. He is on the board for Michael J Fox Foundation, National Space Board Research Institute, Zambon. He has stock in Clintrex which provides consulting services for AstraZeneca, Accorda/Civitas, Biotie, Britannia, Corium, Cynapsus, Cytokinetics, Dart, EMD Serono, Flex, Forward, GeNeuro, Intec, Jazz, Melior, Michael J Fox Foundation, Lundbeck, Lysosomal Therapeutics, Medday, Neuroderm, Neuromedix, Neuropore, Osmotica, Otonomy, Otsuka/INC, Pfizer, Pharma2B, Prana, Raptor, Remedy, Sanofi/Genzyme, Serina, Sunovion, Synagile, Teva, Titan, Ultragenyx, Upsher Smith, US WorldMeds, Vaccinex, Weston Foundation.

Note to the Editor

touchNEUROLOGY (a division of Touch Medical Media) publishes

European Neurological Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of neurology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchNEUROLOGY.com

For inquires please contact:

Carla Denaro - Managing Editor

T: +44 (0) 207 193 6093

managingeditor@touchmedicalmedia.com

Providing practical opinion to support best practice for busy healthcare professionals.


'/>"/>
SOURCE touchNEUROLOGY
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Anaphylaxis Pipeline Market Global Review Research for H2 2016
2. Canadian Addiction Recovery Network Reviews Fentanyl Crisis in Canada
3. U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment
4. New Review of Taking a Clear View - Efficacy and Durability of Aflibercept in Neovascular Age-related Macular Degeneration
5. Ovarian Cancer - Pipeline Review, H2 2016
6. RxWiki Launches First Ever Patient Verified Reviews for 1400+ Pharmacy Brands
7. Post Operative Nausea And Vomiting - Pipeline Review, H2 2016
8. Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections - Pipeline Review, H2 2016
9. Metastatic Breast Cancer - Pipeline Review, H2 2016
10. Globoid Cell Leukodystrophy (Krabbe Disease) - Pipeline Review, H2 2016
11. Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... 2017 Therapix Biosciences Ltd. (Nasdaq: TRPX), ... the development of cannabinoid-based drugs, today announced that ... at three upcoming scientific and investor conferences in ... Invitational: ...                     Wednesday, June ...
(Date:5/23/2017)...  Leaf Healthcare, recognized for developing one of ... ulcer prevention, will unveil its comprehensive mobility monitoring ... Nurses, National Teaching Institute and Critical Care Exposition ... Patient Monitoring System is the first mobility monitoring ... system seamlessly tracks patient movement throughout the mobility ...
Breaking Medicine Technology:
(Date:6/23/2017)... ... June 23, 2017 , ... The Rhode Island ... Care Management Alerts and Dashboards, an innovative new service enabling healthcare providers to ... Care Management Alerts and Dashboards provide near real-time data about patients admitted to ...
(Date:6/23/2017)... ... ... Studies show evidence that carotenoids and antioxidants derived either from the diet or ... But how often do ophthalmologists and optometrists in Sweden recommend the use of nutritional ... early symptoms of AMD? A study published recently in Dove Medical Press ...
(Date:6/23/2017)... ... June 23, 2017 , ... Everybody has their own personal preference when it ... it, and some people don't like it at all. FindaTopDoc took a look at ... Erotic literature can give readers a taste of their deepest, darkest fantasies and has ...
(Date:6/23/2017)... ... June 23, 2017 , ... Georgia State University will ... 20. , The two-day conference is focused on advancing scientific knowledge about the ... lives and eliminating racial breast cancer-related disparities. The conference theme is “Illuminating Actionable ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... Private Flood Insurance offerings. With the Federal Emergency Management Agency’s (FEMA) recent update ... the United States. In 2012, the Biggert-Waters Act was enacted to reflect the ...
Breaking Medicine News(10 mins):